Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Despite Ranbaxy Setback, Indian Cos' Drug Research Stays on Course (India)

This article was originally published in PharmAsia News

Executive Summary

The malaria drug industry faced a major setback following the withdrawal of funding by the Medicines for Malaria Venture (MMV) from an attempt by Ranbaxy Ltd. to develop a new antimalarial treatment. Although Ranbaxy plans to go forward, without funding some are skeptical of the drug's chances. However, two other Indian companies also have promising antimalarial drugs in development. Ipca Laboratories Ltd. leads the pack with four prospects. Two of these molecules are being developed with the support of the Central Drug Research Institute and are currently in preclinical or phase I trials. A third molecule, developed by the Indian Institute of Science, is also in preclinical trials. Ipca's fourth drug in the works is just a new dosage of an older treatment. The fifth drug is being tested by Unimark Pharma Ltd. with the support of the MMV. All five drugs are based on some combination of arteminsinin, a Chinese herb. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts